Introduction
The gastrointestinal tract is a primary site for both HIV-1 transmission and pathogenesis. As the largest secondary lymphoid organ in the body, the gastrointestinal tract harbors the majority of the body's T-lymphocyte population, the primary target cell for HIV-1 infection [1] . The rectal mucosa is uniquely susceptible to HIV-1 infection [2] , and rectal transmission accounts for over 60% of new infections in the United States [3] . During acute HIV-1 infection the gastrointestinal mucosa is the site of rapid T-cell depletion, regardless of transmission site [4] [5] [6] [7] . The gastrointestinal compartment is one of the largest latent reservoirs harboring persistent HIV-1 during chronic infection [8, 9] .
The degree of mucosal inflammation plays a pivotal role in HIV-1 transmission and replication. Activated mucosal CD4 þ T lymphocytes are among the major initial HIV-1 target cells [10, 11] . At baseline, the rectal mucosa represents a physiologically inflamed environment, with an abundance of activated lamina propria and intraepithelial CD4
þ T lymphocytes which could in part explain the increased susceptibility of this compartment [12, 13] . Indeed, our group has previously shown that rectal mucosal cytokine profiles correlate with tissue HIV-1 levels in vivo, supporting the importance of the immune milieu in fostering viral replication in this compartment [14] . During the course of untreated HIV-1 infection, the colonic mucosa exhibits chronically active inflammation comparable with that seen in the active phases of inflammatory bowel disease (IBD) [15] . This chronic inflammatory state, related at least in part to gastrointestinal mucosal inflammation and dysfunction, leads to increased morbidity and mortality due to inflammation-related conditions in HIV-positive patients, such as cardiovascular risk, frailty, and non-AIDS-related malignancies [16] . Therefore, therapies which target this inflammatory cascade could potentially reduce the incidence of these HIV comorbidities.
MicroRNAs (miRs) are small noncoding RNAs that exert posttranscriptional regulation of gene expression via direct binding in the 3 0 untranslated regions (3 0 UTRs) of mRNA targets [17, 18] . Although miRs constitute a small fraction of the human genome, they play an ever increasing role in inflammation and disease [19, 20] . MiRs help regulate immune activation, including T-cell activation and cytokine signaling [21, 22] . Increasing evidence supports a role of miRs in HIV-1 infection. Although there are conflicting reports on the existence of HIV-encoded viral miRs (reviewed in [23] ), the roles of cellular miRs are better understood. Suppression of miR processing machinery in HIV-infected cells increases HIV-1 replication, suggesting that host cell miRs may influence HIV-1 pathogenesis [24, 25] . Indeed, miRs can regulate HIV-1 infection both by direct interaction with viral mRNA [25, 26] , as well as regulation of other cellular proteins [27] [28] [29] . Changes in miR expression have also been associated with elite controller and HIV-exposed seronegative phenotypes [30] [31] [32] [33] . The majority of the data investigating miRs in HIV-1 infection has focused on early infection and peripheral blood cells. Less is known about the role of miRs in more chronic HIV-1 infection and changes in expression at sites other than peripheral blood.
Given the central role of the gastrointestinal tract in HIV-1 infection and inflammation, we sought to examine the expression of miRs at this site in patients with chronic HIV-1 infection. miRs have a known role in regulation of gastrointestinal mucosal inflammation, and deregulation of specific miRs has been associated with other inflammatory disease states such as IBD [34] . As HIV-1 infection similarly induces mucosal inflammation, we sought to identify unique miRs associated with HIV-1-related inflammation which could provide new therapeutic targets to reduce inflammation. Here we identify a specific miR signature present in the gastrointestinal tract of HIV-1-infected patients, and further identify and validate gene targets in the inflammatory pathway.
Methods

Ethics statement
This study was approved by the UCLA Office of the Human Research Protection Program Institutional Review Board (IRB) and all patients signed written informed consent at the time of biopsy collection.
Study patients and colon tissue samples
Sigmoid colon tissue samples from HIV-infected (n ¼ 30), active inflammatory bowel disease (n ¼ 19), and healthy control (n ¼ 7) patients for use in miR-array and PCR experiments were obtained from the UCLA Mucosal Immunology Core Laboratory biorepository (UCLA IRB no. 11-001592). Sigmoid colon mucosal biopsies for explant experiments were obtained from healthy HIV seronegative patients from the UCLA Mucosal Immunology Core Laboratory registry (UCLA IRB no. 10-000528). Sigmoid colon mucosal biopsies (approximately 8 mm Â 2 mm Â 1 mm) were collected via flexible sigmoidoscopy using large cup endoscopic biopsy forceps (Microvasive Radial Jaw no. 1589, outside diameter 3.3 mm) taken 25-30 cm from the anal verge. Biopsies were immediately placed in RPMI 1640 media then used for explant set-up. For HIV-infected participants, viral load, CD4 þ T-cell count, and antiretroviral medications were recorded at the time of collection.
RNA isolation from human colonic biopsies RNA was extracted from snap frozen colonic biopsies after homogenization using Trizol (Invitrogen, Carlsbad, California, USA) according to the manufacturer's instructions, as previously described [35] . The quality of the samples was evaluated by estimating the ratios of A260/A230 and A260/A280 nm for phenol and protein contamination, respectively, using microplate spectrophotometer (Synergy HT; BioTek; Winooski, Vermont, USA), only samples with ratios at least 1.8 were used in further analysis. The integrity of the RNA was further evaluated using the Bioanalyzer 2100 (Agilent, Santa Clara, California, USA) and only samples with RNA integrity number higher than 7.0 were included in the study.
MicroRNA-array analysis miR-array analysis was performed using RNA extracted from colonic biopsies obtained from HIV-infected patients with undetectable plasma viral load (<50 copies/ml, n ¼ 9) and high plasma viral load (>5000 copies/ml, n ¼ 8) using the miRCURY miR Array Profiling service (Exiqon Inc., Woburn, Massachusetts, USA) with background subtraction and normalization performed. Differential expression of miRs between groups was determined using cutoff fold change more than 3 and P less than 0.05 (Student's t test). Data were further parsed using DIANA miR pathway software (miRPath v3, http://snf-515788.vm.okeanos.grnet.gr/) to identify miRs with known roles in inflammatory pathways. The Targetscan algorithm (www.targetscan.org) was used to identify potential direct targets for candidate miRs.
Quantitative PCR analysis miR levels were assessed by quantitative PCR (qPCR) on a CFX384 detection system (Bio-Rad, Hercules, California, USA) with SYBR Green using the Exiqon PCR primer sets according to manufacturer's instructions (Exiqon Inc.). Data were normalized to reference gene expression U6 snRNA and 5S rRNA. All primers for miRs and the reference genes were purchased from Exiqon Inc. Quantitative PCR for cytokines and reference genes GAPDH or b-actin was performed similarly using CFX384 detection system (Bio-Rad) and SYBR Green. Primers were as noted (Supplementary Table 1 , http://links.lww.com/QAD/B127) and data normalized to reference gene expression.
HIV-1 virus expansion
The following reagent was obtained from the NIH AIDS Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH: HIV-1 BaL from Dr Suzanne Gartner, Dr Mikulas Popovic, and Dr Robert Gallo. Stocks of HIV-1 BaL were prepared by infection using PM1 cells. Tissue culture infectious dose (TCID 50) was determined by titration using pooled peripheral blood mononuclear cells. The same viral stock was used throughout the study.
HIV-1 infection of explants and Jurkat cells
Gut mucosal explants were processed as previously described [36] . Briefly, sigmoid biopsies were collected and cultured using RPMI 1640 medium with 2.5 mg/ml amphotericin B and 0.1 mg/ml piperacillin-tazobactam in a 378 humidified incubator. Triplicate biopsies were infected with HIV-1 BaL 1 Â 10 4 TCID 50 for 2 h then thoroughly washed and replaced with fresh media on absorbable gelatin sponge in separate wells of standard tissue culture plates. Total RNA was then isolated at indicated time points for qPCR assays. Jurkat-CCR5 cells were kindly provided by Dr Betsy Herold. 1 Â 10 5 cells were infected with HIV-1 BaL at multiplicity of infection 0.1 for 2 h then washed and replace with fresh media.
Cells were harvested for RNA isolation at designated time points.
MicroRNA transfection
Jurkat-CCR5 cells were transfected using RNAiMAX reagent with 100 nmol/l of miR-26a or miR-29a mimics or the negative control no. 1 (miR-NC) (miRVana, Life Technologies, Carlsbad, California, USA) in OptiMEM medium. Medium was replaced with 10% FBS containing medium after overnight incubation.
3
0 -Untranslated region luciferase assay Luciferase reporter plasmids pLightSwitch carrying the 3 0 UTR of IL6 or STAT3 (Switchgear Genomics, Carlsbad, California, USA) were used for the 3 0 UTR luciferase experiments. Sequential transfection was performed; first, Jurkat-CCR5 cells were transfected with the reporter plasmid (4-mg plasmid per 1 Â 10 6 cells) using FuGENE6 (Promega, Madison, Wisconsin, USA) and 24 h later the same cells were transfected with a final concentration of 50 nmol/l of miR-26a or miR-29a or the respective negative controls. After 24 h the cells were lysed and luciferase activity was measured using the Promega Luciferase Reporter Assay System.
STAT3 ELISA assay
The phosphorylation status of STAT3 in tyrosine 705 (p-STAT3) was assessed by sandwich ELISA assay (Bio-Rad) using cell lysates following transfection with mimics of miR-29a or appropriate negative controls as described above.
Statistical analysis
Data from clinical specimens were analyzed with nonparametric Mann-Whitney test (Fig. 1) . Experimental data were compared using unpaired t tests (Figs. 2-4 ). All statistical analyses were performed using GraphPad Prism (GraphPad Software, La Jolla, California, USA).
Results
Study patients
Our study aimed to identify unique miRs involved in colonic mucosal inflammation during chronic HIV-1 infection. To do this, we used sigmoid mucosal biopsies obtained from two cohorts of HIV-infected patients: first, undetectable viral load (uVL) (plasma viral concentration <50 copies/ml) on suppressive antiretroviral therapy (ART) and second, high viral load (hVL) (plasma viral concentration >5000 copies/ml) either treatment-naïve or off ART for at least 6 months. As an inflammatory control, we used biopsies obtained from HIV-seronegative patients with active IBD, both ulcerative colitis and Crohn's disease colitis. HIV-seronegative healthy control patients were used as a baseline negative control.
Demographics of these cohorts, including mean CD4 þ T-cell counts and viral concentration for HIV-infected patients, are shown in Table 1 .
Identification of 12-microRNA signature in colonic mucosa of HIV-infected patients To examine the potential role of miRs in HIV-1 pathogenesis in the colonic mucosa, we performed miR profiling analysis in colonic tissues from HIVinfected patient with undetectable (n ¼ 9, uVL) and high (n ¼ 8, hVL) plasma viral concentrations. We chose to compare aviremic and viremic patients to identify miRs expressed during the time of active viral replication, with the hypothesis that these miRs are more likely involved in direct pathogenesis of the virus and inflammation. Using a stringent three-fold change and P less than 0.05 cutoff, this analysis revealed 12 miRs that were significantly differentially expressed between the uVL and hVL colonic tissue (Fig. 1a) . Specifically, three miRs (miR-181a, miR-23a, miR-491) were up-regulated, Relative specificity examined by quantitative PCR for microRNA-26a and (f) microRNA-29a levels in colonic biopsies of active inflammatory bowel disease participants (n ¼ 19). Relative levels are normalized to reference targets U6 snRNA and 5S rRNA. Line indicates the median with error bars showing interquartile range. Ã P < 0.05, ÃÃ P < 0.01, ÃÃÃ P < 0.001 and ns, not significant, using Mann-Whitney test.
while nine miRs (miR-4288, miR-29a, miR-26a, let-7b, miR-451, miR-142, miR-190, miR-195, miR-27b) were downregulated in high versus undetectable viremia tissues.
miR-26a and miR-29a are downregulated in the colonic mucosa during active HIV-1 infection From the miRs identified in the array analysis, we were most interested in those that may be regulating the ongoing inflammation seen during chronic HIV-1 infection. To parse this list, we used DIANA miRPath to identify miRs with known regulatory roles in inflammatory pathways [37] . Three miRs were selected using these criteria (Fig. 1b) . As miR-26a and miR-29a have been previously shown to coordinately regulate pathways [38] , including inflammatory [39] , we chose to use these for further study. The role of let-7b is the subject of separate, ongoing investigation.
To confirm our array findings, we quantified miR-26a and miR-29a levels using a second validation cohort of HIV-1-infected patients (n ¼ 11, uVL and n ¼ 12, hVL) using qPCR. To establish the validity of qPCR as a confirmatory readout, this second cohort also included replicate RNA from the same individuals as used in the array when available (designated with open circles in Fig. 1c and d) . These findings were in agreement with our array data, showing both miR-26a and miR-29a had reduced levels in colonic biopsies from viremic patients compared with aviremic patients (Fig. 1c and d) . To assess relative specificity of these miRs in HIV-induced mucosal inflammation, we examined these miRs in active IBD. Using mucosal biopsies from patients with active colorectal IBD, either ulcerative colitis (n ¼ 13) or Crohn's disease (n ¼ 6), we found that, in contrast to the HIV-infected colonic tissues, miR-26a and miR-29a were increased compared with healthy controls (n ¼ 7) (Fig. 1e and f) .
HIV-1 infection rapidly reduces miR-26a and miR-29a levels in T cells
Although decreased miR-26a and miR-29a levels were seen in colonic tissues from chronic HIV-1 infection (Fig. 1) , the cell types involved are not clear. To examine the expression levels of these two miRs in T cells, the primary target for HIV-1 infection, we used the HIVsusceptible Jurkat-CCR5 T-cell line (Jurkat-CCR5) to examine miR expression following in-vitro HIV-1 infection. In agreement with our observations using whole tissue biopsies, we found decreased miR-26a and miR-29a levels in HIV-infected Jurkat-CCR5 cells 24-h postinfection (Fig. 2a) . We next examined the time course of miR-26a and miR-29a expression at 2, 4, 10, and 24 h postinfection with HIV-1. Significantly, we found that HIV-1 infection leads to decreased miR-26a and miR-29a levels very early (4-h postinfection) (Fig. 2b  and c) , suggesting that miR-26a and miR-29a downregulation is an early event during HIV-1 infection.
miR-26a and miR-29a directly target the IL6-STAT3 signaling pathway miRs regulate gene expression via direct binding on the 3 0 UTR of their target genes to induce mRNA degradation or inhibit protein translation [17] , and potential targets can be predicted through bioinformatics methods. We were interested in identifying miR-26a and miR-29a direct gene targets that may be involved in inflammatory signaling pathways during HIV-1 infection. The TargetScan algorithm predicted 45 genes targeted by miR-26a and miR-29a; however, only two genes (IL-6 and STAT3) were related to inflammatory-immune signaling pathways involved in HIV-1 infection. Both miR-26a and miR-29a have potential binding sites in the 3 0 UTR of IL6 and STAT3 genes, respectively (Fig. 3a) .
To confirm these genes are direct targets of miR-26a and miR-29a, we used a 3 0 UTR luciferase reporter system. Specifically, the 3 0 UTR from each gene was cloned into the reporter plasmid downstream of the luciferase gene, then cotransfected with either miR-26a or miR-29a. In agreement with other studies [40] [41] [42] , we found that IL-6 and STAT3 are indeed direct targets of miR-26a and miR-29a, as evidenced by decreased luciferase activity following transfection with the miR (Fig. 3b) . To further examine these direct interactions in cells relevant to HIV-1 infection, we overexpressed miR-26a and miR-29a in Jurkat-CCR5 T cells then assessed mRNA levels or protein expression of the target genes. As shown, miR-26a overexpression specifically reduced IL-6 mRNA levels, yet did not significantly alter mRNA levels of other inflammatory cytokines IL-8 and IL-1b (Fig. 3c) . Similarly, miR-29a overexpression decreased STAT3 mRNA, though not significantly (Fig. 3d) , but did significantly decrease STAT3 phosphoprotein levels assessed by ELISA (Fig. 3e) . These data show that both miR-26a and miR-29a are indeed direct regulators of IL6/STAT3 pathway in Jurkat-CCR5 T cells, consistent with previous studies in other cell types [40] [41] [42] . Our data further suggest that miR-26a regulates IL-6 at the transcriptional level, while miR-29a regulates STAT3
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posttranscriptionally, which has not been previously demonstrated. Taken together, our results indicate that HIV-1 infection leads to decreased miR-26a and miR-29a levels in the HIV-inflamed colonic mucosa, thereby enabling activation of the proinflammatory IL6-STAT3 signaling pathway.
HIV-1 reduces miR-26a and miR-29a expression levels in HIV-infected colonic explants To confirm our findings in a human tissue model, we infected freshly acquired human colonic explants with HIV-1 BaL then assessed expression of miR-26a, miR-29a, and identified target genes. Using qPCR, we again found that HIV-1 infection significantly reduced both miR-26a and miR-29a levels ( Fig. 4a and b) , with an expected increased IL-6 mRNA (Fig. 4c) . These results support our model of decreased negative miR regulation, resulting in increased IL-6 production in colonic tissue during HIV-1 infection.
Discussion
Although treatment of HIV-1 with combination ART results in sustained viremic control and immune reconstitution, indices of systemic immune activation do not fully normalize [43] [44] [45] [46] . Widespread inflammation of the gastrointestinal tract is one suspected driver of ongoing immune activation via mucosal barrier dysfunction and alterations in intestinal microbiome [47] [48] [49] [50] . Given the comorbidities associated with chronic inflammation, therapeutic efforts to further dampen this systemic response could have great benefit to chronic HIV-infected patients. Here we show marked changes in miR expression specific to HIV-1, and show direct action of these miRs on inflammatory mediators. This may represent an attractive target for adjunctive therapy in HIV-1 infected patients.
Using bioinformatics and molecular approaches we showed that miR-26a and miR-29a can directly regulate the IL-6/STAT3 inflammatory pathway in the context of HIV-1 infection, and do so using both transcriptional and translational mechanisms. Plasma IL-6 levels predict morbidity and mortality in treated HIV-1 infection [51] [52] [53] , underscoring the importance of this pathway in HIV-1 pathogenesis. One potential mechanism linking this pathway to chronic mucosal HIV-1 infection is that IL-6/STAT3 axis favors Th17 T-cell development, which are key cells regulating gut dysfunction and systemic inflammation. Th17 cells are also early targets for HIV-1 infection [54, 55] , suggesting that promotion of Th17 development, via induction of IL-6/STAT3 resulting from miR-26a and miR-29a suppression shortly after infection, would be advantageous to the virus by increasing available target cells and inflammatory signals. However, from a clinical perspective, therapeutic manipulation of this IL-6/STAT3 pathway during chronic-treated HIV-1 infection could further decrease Th17 cells, which may have deleterious effects on the barrier function of the gastrointestinal mucosa [56] . This potential consequence of impacting the IL-6/STAT3
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Effects on the IL-6/STAT3 pathway is but one potential functional readout of these miRs on HIV-1 pathogenesis. In addition to regulating inflammatory response, miR-29a can directly interact with HIV-1 via downregulation of Nef protein and decrease in HIV-1 replication [26] , though this targeting may be limited by secondary structure [57] . Suppression of miR-29a during HIV-1 infection, as seen in our study and also in peripheral blood [57, 58] , is advantageous both by increasing inflammation and avoiding the direct inhibitory effects of this miR on the virus. The mechanism of the decreased miR-26a and miR-29a expression is not clear and may include both direct interactions mediated by the virus or rather a host response to the infection. Although beyond the scope of the current study, further investigation into these mechanisms both in the context of HIV-1 or other gastrointestinal infections is warranted.
Studies of miRs have led to the development of novel therapeutics with great promise for clinical utility. The locked nucleic acid miR-122 inhibitor miravirsen has shown efficacy reducing hepatitis C viremia in chimpanzees [59] , and more recently in a Phase IIa trial [60] . A recent study from our group showed that miR-214 has a critical role in ulcerative colitis and transformation to malignancy, and that direct inhibition of this miR not only improved colitis but also reduced the tumor size and burden [61] , underscoring the potential impact of miR therapeutics across diseases.
Most miRs function as fine tuners of gene expression and therefore alterations of only one to two-fold can be highly significant [62] . It is rare to identify in human tissue samples miRs that are deregulated greater than five-fold; this includes landmark articles in cancer or autoimmune diseases [63] [64] [65] [66] . Our study identified miRs that are deregulated three to 16-fold in HIV-1-infected colonic tissue (Fig. 1a) , suggesting these may have a profound impact on mucosal inflammatory mechanisms. Further, these miRs were decreased in HIV-1-infected participants, but not deregulated in healthy or inflammatory (IBD) controls. Although this study is not an exhaustive comparison of all inflammatory conditions, including other enteric infections, it may suggest a unique mechanism in HIV-1 infection worthy of future investigation. If confirmed in wider studies, these miRs would be attractive targets for adjunctive therapy to potentially further reduce the inflammation associated with chronic HIV-1 infection.
